TTR and polyneuropathy: The graph presents the proportion of participants that were heterozygous for the p.Val50Met variants (labeled as 1) versus TTR+ participants without the p.Val50Met variant (labeled as 0), according to the main principal component of the study, namely, the polyneuropathy (PN), cardiomyopathy (CM), gastrointestinal (GI), and general symptoms (GS) components.